Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Syenex
Evanston, Illinois, United Statessyenex.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Syenex has developed advanced synthetic biology platforms to improve the efficiency and scalability of gene and cell therapy delivery vehicles. Their technologies are designed to accelerate the development of curative therapies by providing best-in-class targeted delivery systems. No clinical trial results are available yet as they primarily serve as an enabling technology provider for other developers.[1][2][4]
- Therapeutic areas
- Oncology
- Modalities
- Gene therapiesCell therapiesExtracellular vesicles (EVs)Engineered viral vectors (e.g., lentiviral, retroviral)[2][3][5]
- Industry
- Drug Discovery Services
02
Partnerships
CTMC (joint venture between MD Anderson Cancer Center and Resilience) – partnership to advance T cell therapy manufacturing using Syenex’s SNX-T1 and SNX-T2 vector systems[5].
Beyond the preview
Go deeper on Syenex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syenex.